Aditi Mehta

Aditi Mehta

Auto-generated profile, based on publicly available information

Aditi Mehta

Department of Ophthalmology, Advanced Eye Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
SPSelwyn Marc Prea
Selwyn Marc Prea
YKYu Xiang George Kong
Yu Xiang George Kong
AMAditi Mehta
Aditi Mehta
MHMingguang He
Mingguang He
JCJonathan G. Crowston
Jonathan G. Crowston
AVAlgis Jonas Vingrys
Algis Jonas Vingrys

4 July 2017 in International Ophthalmology
Verified
Journal Article
Closed access
PDF file
AKAtul Kumar
Atul Kumar
RRRaghav Ravani
Raghav Ravani
AMAditi Mehta
Aditi Mehta
SSSriram Simakurthy
Sriram Simakurthy
CDChirakshi Dhull
Chirakshi Dhull

23 November 2019 in International Ophthalmology
Verified
Journal Article
Closed access
PDF file
MSManpreet Singh
Manpreet Singh
MKManpreet Kaur
Manpreet Kaur
AGAditi Mehta Grewal
Aditi Mehta Grewal
SYSonam Yangzes
Sonam Yangzes
DYDeepti Yadav
Deepti Yadav
PGPankaj Gupta
Pankaj Gupta

1 January 2019 in Indian Journal Of Ophthalmology
Verified
Journal Article
Open access
PDF file
MBMandeep S Bajaj
Mandeep S Bajaj
AMAditi Mehta
Aditi Mehta
NPNeelam Pushker
Neelam Pushker
BCBhavna Chawla
Bhavna Chawla
APAmar Pujari
Amar Pujari
NYNeha Singh Yadav
Neha Singh Yadav
Purpose: A pilot randomized control trial to compare the efficacy and side effects of intralesional and oral propranolol in periorbital and eyelid capillary hemangiomas. Methods: Twenty patients were prospectively randomized to two groups of ten each. Group 1 was initiated on oral propranolol 1 mg/kg/day titrated to final dose of 3 mg/kg/day over 1 week which was continued for 6 months and then tapered over 1 week; Group 2 received 3 doses of direct intralesional propranolol hydrochloride 1 mg/ml; 0.2 ml/cm 4–6 weeks apart. Hemangioma area and corneal astigmatism were measured. Results: Within each group at 6 months there was a significant reduction in area (group 1: 83.48 ± 11.67%,P= 0.0019; group 2: 67.78 ± 21.71%,P= 0.0019) and improvement in astigmatism (pre, post: group 1: 2.98D @ 179.8°, 1.13D @ 179.8°,P= 0.0045; group 2: 1.62D @ 90.16°, 0.75D @ 179.9°,P= 0.0001). There was no difference in area reduction (P = 0.056), change in appearance (P = 0.085), ptosis (P = 0.23) and side effects (lethargy, poor feeding;P= 0.171) between the two groups. Conclusion: Efficacy and side effects with intralesional propranolol are comparable to oral propranolol for periorbital and eyelid lesions.

22 November 2017 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
VGViney Gupta
Viney Gupta
BSBindu I. Somarajan
Bindu I. Somarajan
GWGagandeep Kaur Walia
Gagandeep Kaur Walia
JKJasbir Kaur
Jasbir Kaur
SKSunil Kumar
Sunil Kumar
ASArundhati Sharma
Arundhati Sharma

21 April 2017 in BMJ Case Reports
Verified
Journal Article
Open access
PDF file
APAmar Pujari
Amar Pujari
RCRohan Chawla
Rohan Chawla
RSRashmi Singh
Rashmi Singh
AMAditi Mehta
Aditi Mehta